STAAR Surgical

STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

STAAR Surgical reports robust Q4 performance and eyes U.S. growth

STAAR Surgical's Q4 2022 earnings call highlighted strong performance, growth opportunities in key markets, and strategic investments for future success. Despite challenges in China, the company remains optimistic about market recovery and growth prospects. With a focus on EVO lens adoption and increased investments, STAAR is well-positioned for continued growth and market expansion.

STAAR Surgical excels in Q1 with strong global sales growth

STAAR Surgical's Q1 2023 earnings call highlighted robust global sales growth, positive market reception, and strategic investments for future expansion. The company aims to strengthen its market position through targeted growth strategies and operational enhancements.

STAAR Surgical reports record Q2 sales, eyes global expansion

STAAR Surgical's Q2 2023 performance showcased record sales and growth, driven by the EVO family of ICLs.
The company's strong presence in APAC, particularly China, and confidence in high-growth outlook are notable.
Challenges include market declines and pricing dynamics, but opportunities lie in global expansion and strategic initiatives.
Balancing growth and profitability remains a focus, with ongoing efforts to enhance market presence and address challenges.

STAAR Surgical reports resilient Q3 performance amidst market challenges

STAAR Surgical's Q3 2023 performance reflects continued growth in ICL sales despite challenges.
The company is navigating macroeconomic headwinds while focusing on market-building initiatives.
Despite a decline in operating income, STAAR remains confident in its growth prospects.
STAAR's strategic focus on new products and market expansion positions it for future success.

STAAR Surgical posts robust Q4 results, eyes global expansion opportunities

STAAR Surgical's strong financial performance and strategic initiatives position the company for continued growth and market leadership.
Challenges from market competition and macroeconomic factors require careful navigation, but opportunities in expanding markets and operational enhancements offer avenues for growth.
With a focus on innovation, profitability, and global expansion, STAAR is poised to capitalize on market trends and drive sustainable growth in the coming years.

STAAR Surgical surpasses Q1 sales targets, eyes global expansion

STAAR Surgical's Q1 2024 performance exceeded expectations, driven by strong global sales growth and strategic milestones. Challenges include addressing discrepancies in sales and unit growth. The company is poised to capitalize on opportunities in China, surgeon training, and international expansion.

STAAR Surgical posts robust Q2 results, eyes global expansion

STAAR Surgical's Q2 2024 performance reflects strong sales growth, improved profitability, and a positive outlook for fiscal 2024.
The company's strategic strengths in global market expansion and innovation position it well for future growth and achieving long-term sales targets.
Challenges in managing operating expenses and sustaining growth rates in key markets require continued strategic focus and operational efficiency.
Opportunities in expanding market presence, driving innovation, and leveraging financial strength present avenues for sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.

STAAR Surgical to Report Third Quarter Results on November 2, 2022

Professional Basketball Player Max Strus Kicks Off New Season With Upgraded Vision From Life-Changing EVO ICL Lenses

Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.

Is Staar Surgical (STAA) a Solid Growth Stock? 3 Reasons to Think "Yes"

DexCom

Both sell products addressing persistent health issues that are becoming more common.

2 Evergreen Growth Stocks to Buy and Hold Forever

STAAR Surgical continues to demonstrate the fundamental equity premia investors are seeking out in FY22. The buy thesis remains intact from previous analysis on STAA in our estimate and here I've gone over the company's latest numbers.

Keep Adding To STAAR Surgical Longs, Buy Thesis Remains

Devon Energy

Enphase Energy

First Solar

JinkoSolar Holding

Neurocrine Biosciences

Palo Alto Networks

Invesco Solar ETF

S&P 500 dividend standout Devon Energy leads this weekend's watch list of stocks near buy points in a tough market. The post S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms appeared first on Investor's Business Daily.

S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today provided an update on activities related to the commercial introduction of its EVO Visian® Implantable Collamer® Lenses (EVO) in the U.S. EVO is an FDA-approved vision correction lens designed for the correction/reduction of myopia with and without astigmatism. EVO was approved by the FDA on March 25,

STAAR Surgical Patient Awareness Campaign Launched In New York

Staar Surgical (STAA) is an Incredible Growth Stock: 3 Reasons Why

Align Technology

Both companies are facing headwinds that will soon be a thing of the past.

2 Ravenously Growing Stocks to Buy and Hold No Matter What

Staar Surgical (STAA) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love Staar Surgical (STAA)

Staar Surgical (STAA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Staar Surgical (STAA) a New Buy Stock

Its latest earnings update shows that its products are in hot demand worldwide.

Why STAAR Surgical Stock Is Triumphant Today

Start Time: 16:30 January 1, 0000 5:20 PM ET STAAR Surgical Company (NASDAQ:STAA ) Q2 2022 Earnings Conference Call August 10, 2022, 16:30 PM ET Company Participants Caren Mason - President and CEO Patrick Williams - CFO Brian Moore - VP, Investor, Media Relations and Corporate Development Conference Call Participants Andrew Brackmann - William Blair Bill Plovanic - Canaccord Genuity Chris Cooley - Stephens Inc. Zach Weiner - Jefferies Ryan Zimmerman - BTIG David Saxon - Needham and Company Steven Lichtman - Oppenheimer &Co. Operator Hello, all, and thank you for standing by. Welcome to the STAAR Surgical Second Quarter Financial Results Conference Call.

STAAR Surgical Company (STAA) CEO Caren Mason on Q2 2022 Results - Earnings Call Transcript

Staar Surgical (STAA) delivered earnings and revenue surprises of 68% and 1.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Staar Surgical (STAA) Q2 Earnings and Revenues Beat Estimates

Staar Surgical reported better-than-expected second-quarter metrics, leading STAA stock to rise moderately late Wednesday. The post Leading Medical Stock Staar Surgical Jumps After Nabbing A Second-Quarter Beat appeared first on Investor's Business Daily.

Leading Medical Stock Staar Surgical Jumps After Nabbing A Second-Quarter Beat

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced its partnership with singer, songwriter, and actor, Joe Jonas, to raise awareness of its EVO Visian® Implantable Collamer® Lenses (EVO). EVO is an FDA-approved vision correction lens designed for the correction/reduction of myopia and astigmatism. Joe Jonas had myopia since childhood, which i

STAAR Surgical and Joe Jonas Team Up to Introduce New Life-Changing EVO ICL to Millions of Americans Suffering from Distance Vision Problems

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today reported financial results for the second quarter ended July 1, 2022. Second Quarter 2022 Overview Record Net Sales of $81.1 Million Up 30% and Constant Currency Net Sales of $84.2 Million Up 35% from the Prior Year Quarter Record ICL Sales of $77.9 Million Up 32% and Constant Currency ICL Sales of $80

STAAR Surgical Reports Record Second Quarter Net Sales of $81.1 Million Up 30% Y/Y

Apple

Vertex Pharmaceuticals

These companies have cornered the right markets and are chasing the right long-term trends.

3 Winning Evergreen Stocks to Buy and Hold for the Next 25 Years

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 1, 2022 on Wednesday, August 10, 2022 after the market close. STAAR will host a conference call and webcast on Wednesday, August 10 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operationa

STAAR Surgical to Report Second Quarter Results on August 10, 2022

STAAR Surgical Company presents the fundamental momentum that we feel can drive equity returns into the coming years. Profitability and cash flow metrics stack up well for the company, aligning with quality factors investors are now paying a premium for.

STAAR Surgical: Hard Data Approach Justifies Long-Only Portfolio Allocation

Staar Surgical (STAA) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is Why Growth Investors Should Buy Staar Surgical (STAA) Now

The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Staar Surgical (STAA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 42% Upside in Staar Surgical (STAA): Can the Stock Really Move This High?

If you can do it and still sleep at night, then yes.

Should You Buy Stocks When the Market Crashes?

The consensus price target hints at a 47.1% upside potential for Staar Surgical (STAA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 47% Upside in Staar Surgical (STAA): Can the Stock Really Move This High?

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that more than two million Visian® Implantable Collamer lenses (“ICLs”) have been sold globally, including more than one and a half million of the company's latest generation of implantable lenses – EVO Visian® ICLs (“EVO”). New to the U.S. market, EVO is available in more than 75 countries a

News for STAAR Surgical Stock (STAA)